Creo Medical 2024 Results Roadshow Earnings

Creo Medical Group plc presents FY2023 financial results and FY2024 outlook, highlighting total sales of £30.8m and 2.5x revenue increase from Speedboat Inject and CROMA products. The company achieved 49.6% gross margin and reduced underlying operating losses, with strong Q1-24 trading and growing consumables sales supporting continued growth plans.